2026-10-13T23:25:44Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33995319 2026-10-01T11:12:23Z category_67901 category_67907 portal_1154 item_type_7 month_year_10_2026

Congress presentation: IMS 2026 Effects of elinzanetant on sleep disturbance in women with differing baseline vasomotor symptom frequency: results from the OASIS-3 clinical trial Claudio Soares (9642216) Rossella E. Nappi (2744353) Marla Shapiro (4616977) Christian Seitz (2722336) Senka Djordjevic (21842853) Ioanna Gkioni (21842866) Nick Panay (9315613) Menopause Sleep OASIS-3 <p dir="ltr">Presentation from IMS 2026 to communicate elinzanetant decreased sleep disturbance more than placebo regardless of baseline VMS frequency by Week 4, with improvements maintained until study end.</p> 2026-10-01T11:12:23Z Text Presentation 10.71943/bayer.figshare.33995319.v1 https://figshare.com/articles/presentation/Congress_presentation_IMS_2026_Effects_of_elinzanetant_on_sleep_disturbance_in_women_with_differing_baseline_vasomotor_symptom_frequency_results_from_the_OASIS-3_clinical_trial/33995319 CC BY-ND